Ionis Pharmaceuticals

Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. The company has two commercial medicines, SPINRAZA and TEGSEDI. SPINRAZA (nusinersen) injection for intrathecal use is a survival motor neuron-2, directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy in pediatric and adult patients. TEGSEDI (inotersen) injection is a Generation 2+ antisense medicine and an approved subcutaneous RNA-targeting medicine designed to treat people with polyneuropathy caused by hereditary transthyretin amyloidosis.
  • TickerIONS
  • ISINUS4622221004
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
IONS Ionis Pharmaceu... (Health Care)

IONIS PHARMACEUTICALS sees an upgrade to Neutral thanks to a better st...

The independent financial analyst theScreener just awarded an improved star rating to IONIS PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 36.89 and its target price was estimated at USD 30.64.

Valens Research
  • Valens Research
IONS Ionis Pharmaceu... (Health Care)

IONS - Embedded Expectations Analysis - 2021 04 19

Ionis Pharmaceuticals, Inc. (IONS:USA) currently trades at a premium relative to UAFRS-based (Uniform) assets, with a 2.0x Uniform P/B. At these levels, the market has expectations for profitability to remain stable, but management may be concerned about their medicine and technology investments, drug and treatment studies, and their LICA platform Specifically, management may have concerns about their new technology enhancements to the antisense platform, the results of their ENaC cystic fibrosis clinical trials, and the progress of their acromegaly program. In addition, they may lack confide...

IONS Ionis Pharmaceu... (Health Care)

Ionis Pharmaceuticals Inc: 1 director sold

A director at Ionis Pharmaceuticals Inc sold 10,000 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Morningstar | Ionis Reports Solid 1Q Results and Pipeline Progress; Sl...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, but we're waiting for evidence that the firm's newly approved drugs and phase 3 drug candidates can m...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Ionis Reports Solid 1Q Results and Pipeline Progress; Slightly Increas...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, b...

IONS Ionis Pharmaceu... (Health Care)

IONIS PHARMACEUTICALS sees an upgrade to Neutral thanks to a better st...

The independent financial analyst theScreener just awarded an improved star rating to IONIS PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 36.89 and its target price was estimated at USD 30.64.

Valens Research
  • Valens Research
IONS Ionis Pharmaceu... (Health Care)

IONS - Embedded Expectations Analysis - 2021 04 19

Ionis Pharmaceuticals, Inc. (IONS:USA) currently trades at a premium relative to UAFRS-based (Uniform) assets, with a 2.0x Uniform P/B. At these levels, the market has expectations for profitability to remain stable, but management may be concerned about their medicine and technology investments, drug and treatment studies, and their LICA platform Specifically, management may have concerns about their new technology enhancements to the antisense platform, the results of their ENaC cystic fibrosis clinical trials, and the progress of their acromegaly program. In addition, they may lack confide...

IONS Ionis Pharmaceu... (Health Care)

Ionis Pharmaceuticals Inc: 1 director sold

A director at Ionis Pharmaceuticals Inc sold 10,000 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Morningstar | Ionis Reports Solid 1Q Results and Pipeline Progress; Sl...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, but we're waiting for evidence that the firm's newly approved drugs and phase 3 drug candidates can m...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Ionis Reports Solid 1Q Results and Pipeline Progress; Slightly Increas...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, b...

IONS Ionis Pharmaceu... (Health Care)

IONIS PHARMACEUTICALS sees an upgrade to Neutral thanks to a better st...

The independent financial analyst theScreener just awarded an improved star rating to IONIS PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 36.89 and its target price was estimated at USD 30.64.

Valens Research
  • Valens Research
IONS Ionis Pharmaceu... (Health Care)

IONS - Embedded Expectations Analysis - 2021 04 19

Ionis Pharmaceuticals, Inc. (IONS:USA) currently trades at a premium relative to UAFRS-based (Uniform) assets, with a 2.0x Uniform P/B. At these levels, the market has expectations for profitability to remain stable, but management may be concerned about their medicine and technology investments, drug and treatment studies, and their LICA platform Specifically, management may have concerns about their new technology enhancements to the antisense platform, the results of their ENaC cystic fibrosis clinical trials, and the progress of their acromegaly program. In addition, they may lack confide...

IONS Ionis Pharmaceu... (Health Care)

Ionis Pharmaceuticals Inc: 1 director sold

A director at Ionis Pharmaceuticals Inc sold 10,000 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Morningstar | Ionis Reports Solid 1Q Results and Pipeline Progress; Sl...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, but we're waiting for evidence that the firm's newly approved drugs and phase 3 drug candidates can m...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Ionis Reports Solid 1Q Results and Pipeline Progress; Slightly Increas...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, b...

IONS Ionis Pharmaceu... (Health Care)

IONIS PHARMACEUTICALS sees an upgrade to Neutral thanks to a better st...

The independent financial analyst theScreener just awarded an improved star rating to IONIS PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 36.89 and its target price was estimated at USD 30.64.

Valens Research
  • Valens Research
IONS Ionis Pharmaceu... (Health Care)

IONS - Embedded Expectations Analysis - 2021 04 19

Ionis Pharmaceuticals, Inc. (IONS:USA) currently trades at a premium relative to UAFRS-based (Uniform) assets, with a 2.0x Uniform P/B. At these levels, the market has expectations for profitability to remain stable, but management may be concerned about their medicine and technology investments, drug and treatment studies, and their LICA platform Specifically, management may have concerns about their new technology enhancements to the antisense platform, the results of their ENaC cystic fibrosis clinical trials, and the progress of their acromegaly program. In addition, they may lack confide...

IONS Ionis Pharmaceu... (Health Care)

Ionis Pharmaceuticals Inc: 1 director sold

A director at Ionis Pharmaceuticals Inc sold 10,000 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Morningstar | Ionis Reports Solid 1Q Results and Pipeline Progress; Sl...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, but we're waiting for evidence that the firm's newly approved drugs and phase 3 drug candidates can m...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Ionis Reports Solid 1Q Results and Pipeline Progress; Slightly Increas...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, b...

IONS Ionis Pharmaceu... (Health Care)

IONIS PHARMACEUTICALS sees an upgrade to Neutral thanks to a better st...

The independent financial analyst theScreener just awarded an improved star rating to IONIS PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 36.89 and its target price was estimated at USD 30.64.

Valens Research
  • Valens Research
IONS Ionis Pharmaceu... (Health Care)

IONS - Embedded Expectations Analysis - 2021 04 19

Ionis Pharmaceuticals, Inc. (IONS:USA) currently trades at a premium relative to UAFRS-based (Uniform) assets, with a 2.0x Uniform P/B. At these levels, the market has expectations for profitability to remain stable, but management may be concerned about their medicine and technology investments, drug and treatment studies, and their LICA platform Specifically, management may have concerns about their new technology enhancements to the antisense platform, the results of their ENaC cystic fibrosis clinical trials, and the progress of their acromegaly program. In addition, they may lack confide...

IONS Ionis Pharmaceu... (Health Care)

Ionis Pharmaceuticals Inc: 1 director sold

A director at Ionis Pharmaceuticals Inc sold 10,000 shares at 60.000USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Morningstar | Ionis Reports Solid 1Q Results and Pipeline Progress; Sl...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, but we're waiting for evidence that the firm's newly approved drugs and phase 3 drug candidates can m...

Karen Andersen
  • Karen Andersen
IONS Ionis Pharmaceu... (Health Care)

Ionis Reports Solid 1Q Results and Pipeline Progress; Slightly Increas...

Ionis' first-quarter results were on track with our expectations. We're increasing our global probability of approval for rare disease drug Tegsedi from 70% to 80%, following the recent European approval, and plan to increase our assumed probability of approval for ALS drug tofersen following recent early data. We expect to slightly raise our current $52 per share fair value estimate as a result. Overall, Ionis' antisense technology is gaining traction and could lead to the creation of a moat, b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch